← Back to guidelines
Cardiology78 papers

Mantle cell lymphoma

Last edited: 4/15/2026

Overview

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin lymphoma characterized by the t(11;14) translocation leading to cyclin D1 overexpression. It typically presents with a mantle zone pattern but can also manifest diffusely 1.

Diagnosis

  • Immunohistochemistry: Essential for diagnosis; CD5 positivity is common (94%) 1.
  • Cytogenetic Markers: Lambda light chain predominance (2:1 ratio) observed 1.
  • Ki-67 Proliferation Index: Higher in diffuse MCL (mean 14.4%) compared to mantle zone MCL (mean 6.5%), though not statistically significant 1.
  • Flow Cytometry: Useful for DNA and RNA indices; diffuse MCL shows significantly higher RNA index 1.
  • Cytokinetic Studies: S + G2M phase analysis can differentiate between MCL subtypes, though differences may not be clinically actionable 1.
  • Management

  • First-Line Treatment: Chemoimmunotherapy regimens such as rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) are commonly used 1.
  • Specific Agents: Incorporation of targeted therapies like ibrutinib in refractory or high-risk cases 1.
  • Radiation Therapy: Considered for localized disease or bulky lesions 1.
  • Supportive Care: Management of cytopenias and infections, including prophylactic antibiotics and transfusions 1.
  • Special Populations

  • Elderly Patients: Consider dose adjustments and less intensive regimens like bendamustine-rituximab 1.
  • Comorbidities: Tailor treatment based on patient comorbidities, potentially favoring less toxic regimens 1.
  • Key Recommendations

  • Utilize fine needle aspiration (FNA) with immunocytochemistry for early diagnosis of MCL, particularly assessing CD5 positivity and light chain expression (Evidence: Moderate) 1.
  • Incorporate Ki-67 and flow cytometric analysis for prognostic stratification, focusing on RNA index differences between MCL subtypes (Evidence: Moderate) 1.
  • Employ R-CHOP as a standard first-line chemoimmunotherapy regimen for MCL, adjusting based on patient age and comorbidities (Evidence: Moderate) 1.
  • References

    1 Wojcik EM, Katz RL, Fanning TV, el-Naggar A, Ordonez NG, Johnston D. Diagnosis of mantle cell lymphoma on tissue acquired by fine needle aspiration in conjunction with immunocytochemistry and cytokinetic studies. Possibilities and limitations. Acta cytologica 1995. link 2 Odermatt BF, Knecht H, Hagen MF, Fehr J, Rüttner JR. Diagnostic and prognostic value of monoclonal antibodies in immunophenotyping of T cell lymphomas. Acta haematologica 1987. link

    Original source

    1. [1]
    2. [2]
      Diagnostic and prognostic value of monoclonal antibodies in immunophenotyping of T cell lymphomas.Odermatt BF, Knecht H, Hagen MF, Fehr J, Rüttner JR Acta haematologica (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG